October 6, 2020 -- A new cancer treatment called double chimeric antigen receptor (CAR) T therapy for relapsed/refractory B-cell non-Hodgkin lymphoma has advanced to a phase II clinical trial. Positive results from the phase I trial were published October 5 in Nature Medicine.
The therapy was developed at the Medical College of Wisconsin in Milwaukee. It targets two proteins, antigens CD19 and CD20, on the surface of cancer cells, and phase I trial results demonstrated that it is safe for use in patients with relapsed B-cell non-Hodgkin lymphomas, the college said in a statement. Within 28 days of undergoing the CAR T-cell therapy, 82% of patients had positive responses; six months later, more than half remained in remission.
"Immuno-oncology using T-cell treatments shows incredible promise for cancer patients," principal investigator Dr. Nirav Shah said in the statement. "This is a giant leap forward in personalized medicine."
The phase II trial will further establish the therapy's efficacy, according to the college.
Copyright © 2020 scienceboard.net